DB 0003
Alternative Names: DB-0003Latest Information Update: 28 May 2021
At a glance
- Originator DongKoo Bio&Pharma
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 28 May 2021 No recent reports of development identified for clinical-Phase-Unknown development in Hypertension in South Korea
- 09 Apr 2018 Clinical trials in Hypertension in South Korea (unspecified route) (DongKoo Bio&Pharma pipeline, April 2018)